There are some good points there Hdavid. The 34% reduction in...

There are some good points there Hdavid. The 34% reduction in losses was something I didn't notice. Thanks for pointing it out.

Based on above and the current price, I think it's a buy ( but very risky, I am down -20% ) but because of HIV potential, not Covid.
Covid may be a raging success but it is more unpredictable.
With HIV, they are first to market. That's it.

John Kelly obviously has to be an advocate for his own company. He is invested in it.
The one area he seems to overstate, as I mentioned, is the 'bits in a box' claim that AT1 has superior design.
I don't find this to be true, and other HIV tests have performed just as well.